Colomer et al. discover that IKKa kinase contributes to the chemo-and radioresistance of cancer cells by facilitating ATM activation and DNA repair. BRAF inhibitors prevent damage-induced IKKa activation, leading to the attenuation of ATM signaling and DNA repair. IKKa depletion or BRAF inhibitors combined with 5-FU and irinotecan synergistically enhance the killing of patient-derived xenograft tumors. 
In Brief
Colomer et al. discover that IKKa kinase contributes to the chemo-and radioresistance of cancer cells by facilitating ATM activation and DNA repair. BRAF inhibitors prevent damage-induced IKKa activation, leading to the attenuation of ATM signaling and DNA repair. IKKa depletion or BRAF inhibitors combined with 5-FU and irinotecan synergistically enhance the killing of patient-derived xenograft tumors. 
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INTRODUCTION
The DNA damage response (DDR) maintains genome stability by coordinating the cell cycle, DNA repair, and apoptosis in response to DNA lesions. Following DNA double-strand breaks (DSBs), the DDR is activated by ATM-dependent phosphorylation of numerous targets, including the effector kinase Chk2 and the histone H2A.X (called gH2A.X when phosphorylated). Dependent on cell-cycle stage, ATM coordinates the recruitment of 53BP1 or BRCA1 to damaged DNA, which determines DSB repair pathway choice and whether the lesion is repaired by non-homologous end joining (NHEJ) or homologous recombination (HR). In G1, 53BP1, RIF1, and the Sheldin co-factors oppose DSB resection, thereby favoring NHEJ and opposing HR (Panier and Boulton, 2014) . Conversely, in S-G2, when an intact sister chromatid is available as a template following the completion of S phase, BRCA1 antagonizes 53BP1 and co-factors, thereby promoting a switch in DSB repair pathway to favor HR (Bothmer et al., 2010 (Bothmer et al., , 2011 Chapman et al., 2012a Chapman et al., , 2012b Escribano-Díaz et al., 2013; Zimmermann et al., 2013) . In non-proliferating cells (cells in G0-G1 phases), classical NHEJ is the preferred option for DSB repair since there is no homology donor for HR. From yeast to mammals, multiple genotoxic agents such as UV, ionizing radiation (IR), reactive oxygen species, and 5-fluorouracil (5-FU) also induce the protein kinase p38, which plays an essential role in the regulation of cellular checkpoints (Alao and Sunnerhagen, 2008; Bulavin et al., 2001; Preta et al., 2010; Rouse et al., 1994) . Recently, it was demonstrated that p38a modulates the ATR pathway through direct phosphorylation of CtIP, which promotes therapy resistance in cancer cells (Canovas et al., 2018) . Contemporary treatments for most solid cancers involve surgery, radiotherapy, and combinations of chemotherapies, such as 5-FU, oxaliplatin, and irinotecan (Iri), which eradicate tumors by inducing DSBs in highly proliferative cells (reviewed in Brenner et al., 2014) . However, it is well established that tumors also contain low proliferating and quiescent cells that are therapy resistant and contribute to tumor relapse and metastasis (Batlle and Clevers, 2017) . Beyond non-specific DNA-damaging agents, antibodies targeting epidermal growth factor receptor (EGFR) constitute a second therapeutic option for cancer treatment, with mutations in KRAS and BRAF (two essential elements of the EGFR signaling pathway) that are predictive of treatment failure (Amado et al., 2008; Di Nicolantonio et al., 2008) and poor prognosis (Richman et al., 2009) . Based on the structural characteristics of mutated RAS, the possibility of developing small molecules that revert its activation remains a significant challenge (Vetter and Wittinghofer, 2001) . Thus, there is a growing interest in developing BRAF inhibitors and other inhibitors of the mitogen-activated protein kinase (MAPK) pathway that are being used for treating BRAF-mutated metastatic melanoma (Hu-Lieskovan et al., 2015; Ribas et al., 2014) . However, recent BRAF inhibitor trials in cancer patients carrying BRAF-mutated tumors have produced largely negative results (Hong et al., 2016) .
The nuclear factor kB (NF-kB) signaling pathway regulates innate and acquired immunity and is essential for most physiological processes but also for cancer progression (reviewed in Zhang et al., 2017) . Multiple extracellular stimuli, including the inflammatory cytokines tumor necrosis factor a (TNF-a) and interleukin 1b (IL-1b), induce NF-kB through a series of signaling events that lead to the phosphorylation and activation of a kinase complex that consists of IKKa, IKKb, and IKKg/NEMO. The IKKa subunit is dispensable for NF-kB activation, but it has been found to exert multiple pro-tumorigenic functions. Several studies have demonstrated that IKKa enhances the metastatic activity of prostate tumors (Luo et al., 2007) and squamous cell carcinomas (Toll et al., 2015) by regulating the Maspin gene. Epithelial IKKa is required for the initiation and progression of intestinal adenomas (Colomer et al., 2018) and lung adenocarcinomas (Vreka et al., 2018) in mice. Recently, we identified a nuclear active form of the IKKa kinase, IKKa(p45), which is localized in the nuclear compartment of cancer cells. IKKa(p45) induces the phosphorylation of histone H3 and nuclear co-repressors, which is dependent on its interaction with non-activated full-length IKKa and promotes tumor growth independent of canonical NF-kB signaling (Margalef et al., 2012) . The phosphorylation and activation of IKKa(p45) require the MAP kinases BRAF and TAK1 and take place in proximity to the endosomal compartment (Margalef et al., 2012 . The kinase p38a has also been linked to TAK1 (MAP3K7) and IKK activation in several situations, including the DDR (Chen et al., 2015; Hindi et al., 2018; Yang et al., 2011) . In fact, exposure to chemotherapeutic agents leads to the activation of canonical NF-kB, downstream of ATM and NEMO (Wu et al., 2006) .
Here, we make the unexpected discovery that the activity of BRAF and IKKa kinases is important for a proper DDR and for efficient DNA repair. In response to DNA damage, IKKa(p45) is rapidly activated by phosphorylation on Ser180, it translocates to the nucleus, and it co-localizes with 53BP1 at sites of damage. BRAF inhibition or loss of IKKa(p45) attenuates ATM activation and downstream checkpoint signaling, reduces the phosphorylation of key DDR factors, and compromises DNA repair, including 53BP1-dependent end joining. Finally, we show that BRAF inhibition or IKKa(p45) depletion synergizes with DNA-damaging chemotherapeutic agents to induce tumor eradication in mice, thus revealing a potential therapeutic strategy for cancer treatment.
RESULTS
IKKa(p45) Is Rapidly Activated in Response to DNA Damage IKKa(p45) is a largely uncharacterized kinase with no known substrates. In an attempt to identify processes that are regulated by IKKa, we sought to identify its kinase substrates through quantitative phospho-proteomic analysis of control and IKKa-knockdown HT29 cells. Unexpectedly, this approach identified several DDR pathway components, including 53BP1 and KAP1 (also known as TRIM28 or transcription intermediary factor 1b ), as proteins whose phosphorylation depends on IKKa (see experimental strategy in Figure S1A and the results in Table S1 ). This observation raised the possibility that IKKa may function at some level in the DDR.
To examine this possibility, we exposed HT29 cells to UV light and performed western blot analysis at different time points. UV treatment rapidly induced the phosphorylation of nuclear IKKa(p45) on Ser180 (referred to as p-IKKa(p45)), which preceded the phosphorylation of canonical DDR proteins, including Chk1, KAP1, and H2A.X ( Figure 1A ). Different UV doses comparably increased p-IKKa(p45) levels in the nucleus ( Figure S1B ), and this occurred in a range of different cancer cells independent of the mutational status of KRAS or BRAF (Figures 1B and 1C) . To determine whether the induction of nuclear p-IKKa(p45) extends beyond UV to other DNA-damaging agents, we also examined p-IKKa(p45) in response to IR and the topoisomerase II inhibitor, etoposide. p-IKKa(p45) was rapidly induced in response to all of the tested DNA-damaging agents, although the largest effect was produced by UV treatment ( Figure 1D ). Since p-IKKa(p45) is the nuclear form of activated IKKa, we asked whether it is also recruited to sites of DNA damage. Immunofluorescence analysis revealed that p-IKKa(p45) co-localized with 53BP1 in laser-induced stripes ( Figure 1E ). These results reveal that p-IKKa(p45) is rapidly induced by and accumulates at sites of DNA damage, which raised the possibility that p-IKK (p45) may contribute in some way to the regulation of the DDR pathway.
p38-MAPK Activates IKKa in Response to DNA Damage
The activation of ATM or ATR is an early event in the cellular response to DNA damage, both kinases being essential for initiating the DDR signaling cascade in response to different DNA lesions. To determine whether ATM or ATR contributes to the induction of nuclear p-IKKa(p45) in response to DNA damage, we treated UV-irradiated cells with selective ATM or ATR inhibitors and blotted for IKKa(p45) Ser180 phosphorylation. While ATM and ATR inhibitors effectively abolished the phosphorylation of their downstream effector kinases Chk2 (pT68) and Chk1 (pS345; Figure 2A ), this had no impact on the damage-induced Ser180 phosphorylation of IKKa(p45). We also considered the possibility that the DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) may act redundantly to phosphorylate IKKa(p45) in response to damage. However, the combined inhibition of ATM and DNA-PKc also had no effect on the induction of p-IKKa(p45) following damage ( Figure S2A ). These data, coupled with the fact that p-IKKa(p45) induction precedes many other early damage markers, including gH2A.X and Chk1 ( Figure 1A ), suggested that IKKa(p45) phosphorylation either occurs upstream of or parallel to ATM-ATR activation.
Since IKKa is known to be activated by BRAF, TAK1, and p38-MAPK, we explored whether these kinases may also promote p-IKKa(p45) activation following UV treatment. Selective inhibitors of TAK1, BRAF, or p38-MAPK (but not MEKi) effectively abolished IKKa(p45) Ser180 phosphorylation in response to UV ( Figure 2B ).
Of these kinases, only p38-MAPK and IKKa(p45) were observed to be significantly induced in response to UV treatment ( Figure 2B ). Nevertheless, TAK1 and BRAF inhibitors prevented the activation of p38-MAPK in response to UV, indicating that the basal activity of TAK1 and BRAF are required to prime p38-MAPK for subsequent damage-induced activation ( Figure 2B ).
To add further support to these findings and to exclude potential off-target effects of the p38-MAPK inhibitors, we examined See also Figure S1 and Table S1 . IKKa(p45) phosphorylation in UV-treated p38a-MAPK knockout cells (Adams et al., 2000) . In agreement with our inhibitor experiments, p38a-MAPK knockout cells failed to induce IKKa(p45) phosphorylation in response to UV ( Figure 2C ). p38a-MAPK inhibition also prevented IKKa(p45) Ser180 phosphorylation at multiple time points following UV treatment ( Figure 2D ). Moreover, BRAF inhibition was found to abrogate p-IKKa(p45) induction independent of BRAF mutational status ( Figure 2E ), irrespective of DNA-damaging stimulus ( Figure S2B ), and at a range of different time points ( Figure S2C ). Comparable effects on p-IKKa(p45) induction were also observed using two different BRAF inhibitors, vemurafenib and sorafenib ( Figures S2D and S2E ), which are used in clinical practice. These results establish that IKKa(p45) is rapidly activated in response to DNA-damaging agents downstream of TAK1, BRAF, and p38-MAPK. Notably, we did not detect evidence of nuclear TAK1, BRAF, or p38-MAPK following UV treatment ( Figure 2F ), suggesting that IKKa is principally activated in the cytoplasm, translocates to the nucleus, and accumulates on chromatin.
IKKa and BRAF Facilitate ATM Activation and Downstream DDR Signaling
In light of our findings that IKKa(p45) is rapidly induced by DNA damage, we consider the possibility that p-IKKa(p45) may contribute to the DDR. To investigate this possibility further, we conducted a phospho-proteomic analysis of control and IKKaknockdown HT29 cells either untreated, as before, or subject to UV irradiation for 30 min. We observed that the UV-induced phosphorylation of several DDR components, including 53BP1, MDC1, and KAP1, were compromised in cells lacking IKKa (Figure 3A ; Table S2 ). Western blot analysis of IKKa-knockdown cells exposed to UV at different time points further confirmed that Chk1 phosphorylation on Ser345 and gH2A.X induction is significantly attenuated in IKKa-depleted cells ( Figure S3A ). In contrast, knocking down IKKb or NEMO had no measurable effect on Chk1, Ser345, and histone H2A.X phosphorylation upon UV treatment ( Figure S3B ).
Since H2A.X, MDC1, 53BP1, and KAP1 are known substrates of ATM, we considered the possibility that IKKa(p54) may facilitate ATM activation after UV exposure. Auto-phosphorylation of ATM at Ser1981, which is an established marker of ATM activation, was significantly reduced in IKKa knockout cells exposed to UV ( Figure 3B ). IKKa knockout cells were also compromised for ATM activation following IR ( Figure S3C ) or doxorubicin treatment ( Figure S3D) and at multiple time points tested. Impaired ATM activation in IKKa knockout cells was also associated with attenuated p-Chk2 (T68), p-KAP1 (S824), and gH2A.X levels. Impaired ATM activation following UV exposure was rescued by lentiviral transduction of mCherry-IKKa in the IKKadeficient cells ( Figure 3C ).
Since BRAF is required for IKKa(p45) activation following DNA damage, we assessed the impact of BRAF inhibitors on ATM activation. In agreement with our previous data, inhibition of BRAF significantly reduced ATM activation, as measured by the induction of ATM Ser1981 auto-phosphorylation, and also compromised downstream phosphorylation of DDR markers in UV-( Figure 3D ) and IR-treated ( Figure S3E ) HT29 cells. Similar results were also observed in breast, pancreatic, and melanoma cancer cell lines ( Figure S3F ).
Since the MRE11, RAD50, and NBS1 (MRN) complex is responsible for the recruitment of ATM to sites of DNA damage, we investigated whether IKKa deficiency or BRAF inhibition may affect MRN complex stability. Western blot analysis revealed that the protein levels of the MRN complex were unaffected both in IKKa-deficient cells ( Figure S3G ) and after BRAF inhibition ( Figure S3H ). We also investigated the impact of IKKa knockdown in Rad50 s/s mutant cells, which exhibit a hypermorphic signaling phenotype that suppresses ATM deficiency by activating other phosphatidylinositol 3-kinase (PI3K)-like kinases (Morales et al., 2005) . In contrast to wild-type cells, knocking down IKKa in Rad50 s/s mutant cells did not prevent KAP1 and CHK1 phosphorylation after UV exposure, but instead resulted in the robust activation of these DDR markers ( Figure S3I ). These data suggest that similar to ATM deficiency, the Rad50 s/s allele is capable of suppressing the signaling defects caused by IKKa knockdown, potentially through the activation of other PI3K-like kinases.
IKKa Interacts with and Directly Phosphorylates ATM in Response to DNA Damage Next, we examined whether IKKa and ATM interact upon DNA damage. Immunoprecipitation experiments with an anti-IKKa(p45) antibody detected an interaction between endogenous ATM and both full-length and IKKa(p45), 15 min after UV treatment ( Figure 3E ). This observation raised the possibility that IKKa(p45) may directly phosphorylate ATM in response to DNA damage, potentially contributing to ATM activation. Consistent with this possibility, kinase assays revealed that recombinant IKKa is able to phosphorylate a fragment of ATM comprising amino acids 1,911-2,063 in vitro ( Figure 3F ). The same fragment was also phosphorylated in lysates from IKKa wild-type (WT) but not from IKKa-deficient cells ( Figure 3G ). Mass spectrometry analysis of the in vitro phosphorylated ATM fragment showed that S1974, S1987, S2058, and T2059 are direct substrates of the IKKa kinase ( Figure 3H ). It should be noted that once activated, ATM auto-phosphorylates itself on Ser367, Ser1893, See also Figure S2 . (legend continued on next page) and Ser1981, with the latter commonly used as a marker of ATM activation in vivo. However, these auto-phosphorylation sites are dispensable for ATM activation following DNA damage based on the fact that knockin mice mutated for these three sites exhibit normal downstream DDR signaling (Daniel et al., 2008) . Since the loss of IKKa impairs robust ATM activation, our data raise the possibility that IKKa(p45) phosphorylation of these distinct sites in ATM may facilitate its activation.
IKKa and BRAF Contributes to DNA Damage Resolution
Since ATM activation is important for coordinating DNA repair, we next tested the possible impact of BRAF and IKKa inhibition in promoting lesion resolution. Inhibiting BRAF did not impair the formation of gH2A.X/53BP1 foci at sites of IR-induced DNA damage, but instead imposed a significant delay in lesion resolution ( Figure 4A ), consistent with defective or attenuated DNA repair. Phosphorylation of 53BP1 by ATM is required to recruit Rap1 interacting factor 1 (RIF1) to sites of DNA damage to counteract DSB end resection to promote NHEJ in G1 (Chapman et al., 2012a) . In agreement with our previous observations, co-recruitment of 53BP1 and its cofactor RIF1 was attenuated following BRAF inhibition ( Figure 4B ) or in IKKa knockout mouse embryonic fibroblasts (MEFs) ( Figure 4C ). IKKa-deficient cells or cells subject to BRAF inhibition also exhibited a significant increase in the levels of DNA breaks in UVtreated MEFs as determined by comet assay (Figures 4D and  S4A ). These results suggest that the loss or inhibition of IKKa or BRAF compromises ATM activation and hinders downstream DNA repair.
To further examine the contribution of IKKa and BRAF to 53BP1-dependent DNA repair, we used conditional Trf2
FL/FL
MEFs; inactivation of the shelterin subunit telomeric repeatbinding factor 2 (TRF2) leads to telomere deprotection and chromosome end-to-end fusions mediated by 53BP1-dependent NHEJ (Chapman et al., 2013; Celli and de Lange, 2005) . Following TRF2 inactivation by adenoviral CRE transduction, MEFs were left untreated or treated with BRAF or MEK inhibitors (which do not prevent damage-induced IKKa(p45) phosphorylation; see Figure 2D ) for 72 h and then the cells were processed for metaphase visualization. Using telomere-specific fluorescence in situ hybridization (FISH), cells were scored for the presence of chromosome end-to-end fusions. Consistent with our previous findings, IKKa knockdown ( Figure 4E ) or treatment with BRAF inhibitor ( Figure 4F ) significantly reduced chromosome fusions after Trf2 deletion. In contrast, MEK inhibition did not affect chromosome fusions in Trf2 null MEFs ( Figure S4B ), even though this had a comparable effect on cell-cycle position when compared to the BRAF inhibitor ( Figure S4C ) and IKKa knockdown ( Figure S4D ). Consistent with impaired ATM function, BRAF inhibition precluded RIF1 recruitment to the telomeres after Trf2 deletion ( Figure S4E ). These results further suggest that BRAF and IKKa affect 53BP1 and RIF1 function, thereby allowing the effective resolution of DNA damage by NHEJ in G1.
BRAF and IKKa Inhibition Synergize with DNA DamageBased Therapy in Patient-Derived Tumoroids Current protocols for cancer treatment rely to a large extent on DNA-damaging agents that selectively kill highly proliferative tumor cells but impose a lesser effect on low proliferating cancer cells. Furthermore, PI3K-like kinase inhibitors, including antagonists of ATM, ATR, and DNA-PKcs, are in clinical development to exploit their impact on the DDR. In light of our findings that BRAF and IKKa are required for efficient ATM signaling and DNA repair, we hypothesized that the inhibition of these kinases may synergize with DNA-damaging drugs to promote tumor cell killing. To test this possibility, we treated patient-derived colorectal cancer (CRC) tumoroids ( Figure 5A ), which have been recently validated as models for therapy prescription (Sato et al., 2011; Vlachogiannis et al., 2018) , with suboptimal doses of 5-FU+irinotecan (Iri), alone or in combination with the BRAF inhibitors vemurafenib or AZ628. Consistent with our cellular studies, BRAF inhibition significantly reduced ATM activation and Chk1 phosphorylation in response to damage ( Figure 5B ), with the combination treatment imposing a striking synergistic effect on the eradication of tumoroids compared with single treatments alone ( Figure 5C ). Comparable synergistic effects with BRAF inhibitors were also observed when treating tumoroids with increasing doses of 5-FU+Iri ( Figures 5D and 5E ) or g-irradiation ( Figure S5A ), or using the DNA-damaging agent doxorubicin ( Figure S5B ), which is commonly used in breast cancer treatment but is primarily ineffective against CRC tumors as a single agent.
The loss of CRC tumoroid viability in the combination treatments was also associated with the massive accumulation of DNA damage and induction of apoptosis as determined by gH2A.X and cleaved caspase 3 levels, respectively (Figures 5F, 5G, S5C, and S5D). The enhanced accumulation of DNA breaks in tumoroids subject to the combination treatment was further confirmed by comet assays (Figures 5H and S5E ). Most important, tumoroids subjected to the partial depletion of IKKa by CRISPR-Cas9 and treated with 5-FU+Iri displayed reduced ATM activation ( Figure 5I ) with no significant cell-cycle alterations ( Figure S5F ), and were not further sensitized by BRAF inhibitors ( Figure 5J ). IKKa-depleted tumoroids do not show any reduction in IKKb levels or activity ( Figures 5I and S5G ). These data suggest that BRAF and IKKa inhibition could be exploited to improve tumor killing in combination with DNA-damaging chemotherapy or radiotherapy. See also Figure S3 and Table S2 . two independent patient-derived metastatic tumors (IMIM-X#1 and IMIM-X#3) that possess acquired resistance to regimes of DNA damage-based and EGFR antibody-based therapies (Montagut et al., 2012) . Equivalent volumes of tumor cells were implanted in the cecum of nude mice, and tumor growth was monitored by palpation. At the time of tumor detection, animals were randomly ascribed to the treatment groups: control, 5-FU+Iri, vemurafenib, or 5-FU+Iri plus vemurafenib. The combination of 5-FU+Iri plus vemurafenib significantly reduced tumor growth in vivo compared with single-agent treatments ( Figures  6A and 6B) , and this was associated with the presence of extensive areas of necrosis and fibrosis ( Figure 6C ). Morphologically, residual neoplastic cells displayed a severe pleomorphism after combination treatment, but not with other conditions tested (Figure 6C) , and was associated with the accumulation of DNA damage in the epithelial tumor component ( Figures 6D and 6E) . Notably, the combination treatment did not lead to measurable toxicity, as indicated by the overall aspect of the animals and the absence of anomalous cleaved caspase 3 staining in the colonic tissue adjacent to the implanted tumors ( Figure S6A ). The combination treatment may also affect the invasive nature of these tumors, as we detected only 1 animal with peritoneal implants from 5 animals in this group compared with the controls (5/5 animals with implants) and the single treated animals (5/6 and 3/6 for vemurafenib and 5-FU+Iri, respectively) ( Figure S6B ). Finally, we examined the long-term therapeutic potential of the vemurafenib and 5-FU+Iri combination treatment of IMIM-X#1 tumors in vivo. After a 3-month follow-up, we observed a significant impact on the survival of animals treated with 5-FU+Iri in combination with vemurafenib when compared with vehicletreated, vemurafenib-only, and 5-FU+Iri-treated animals. All of the mice treated with 5-FU+Iri or vemurafenib only died during the course of the experiment due to IMIM-X#1-derived tumor growth. In contrast, six of seven animals treated with 5-FU+Iri plus vemurafenib survived for the duration of the study and were tumor-free at the end of the experiment. There was no evidence of tumor growth in the only mouse that succumbed in this treatment group, which appeared to have died from other causes. The resulting Kaplan-Meier curves ( Figures 6F and 6G ) demonstrate the potent effect of combining BRAF inhibitors with DNA-damaging agents in promoting tumor eradication and long-term survival in vivo.
DISCUSSION
IKKa was previously found to influence tumor initiation and cancer progression through NF-kB-dependent and-independent mechanisms. However, insights into the substrates of IKKa and the pathways that IKKa regulates were unknown. Using an unbiased proteomic analysis to identify IKKa substrates, we have uncovered an unappreciated role for IKKa and its activating kinase BRAF in the DDR pathway. Loss or inhibition of these kinases compromised ATM activation and downstream DDR signaling, impaired DNA repair by 53BBP1-dependent end joining, and synergized with commonly used chemotherapies to induce tumor eradication in vivo. Since these tumors are refractory to killing by single-agent treatments, our proposed combination strategy may have important implications for cancer treatment.
A role for IKKa in the DDR is supported by our findings that IKKa is rapidly activated by phosphorylation on Ser180 in response to a range of DNA-damaging agents and proceeds to accumulate on chromatin at sites of DNA damage. Damage-induced IKKa activation was found to occur independently of the canonical damage-responsive kinases ATM and ATR, but is instead dependent on BRAF, TAK1, and p38-MAPK kinases. We also showed that IKKa interacts with ATM shortly after the introduction of DNA damage, which raised the possibility that IKKa may directly regulate ATM function. Recombinant IKKa was found to directly phosphorylate ATM on four sites distinct from the known ATM auto-phosphorylation sites, including the commonly used activation maker pSer1981. IKKa-deficient cell extracts were also compromised for ATM phosphorylation in vitro, and the loss of IKKa or the inhibition of BRAF was found to attenuate ATM activation both in cells and in tumoroids. In agreement with the observed impairment in ATM activation, IKKa-deficient cells or inhibition of BRAF also resulted in the diminished phosphorylation of Chk1, Chk2, gH2A.X, MDC1, 53BP1, and Kap1 following the induction of DNA damage. We propose that IKKa affects the DDR by facilitating ATM activation. Since ATM auto-phosphorylation sites are dispensable for its activation (Daniel et al., 2008) , future studies should assess the importance of the ATM residues phosphorylated by IKKa.
DDR signaling also plays an important role in coordinating the repair of DNA lesions. The loss or inhibition of IKKa or BRAF was found to delay the resolution of DNA damage, which manifests as the persistence of H2A.X and 53BP1 foci at late time points following the induction of damage. The inhibition of BRAF or loss of IKKa also resulted in persistent tail moments after damage in comet assays. Attenuated damage signaling in these cells is the likely cause of the DNA repair defects, as IKKa-deficient cells exhibit impaired recruitment of RIF1 to the sites of DNA damage, which is dependent on the phosphorylation of 53BP1 by ATM (Chapman et al., 2013) . A role for BRAF and IKKa in The statistical analysis in (C) and (I) was performed by unpaired t test, comparing the combination treatments with single 5FU+irinotecan (red) or BRAF/IKK inhibitors (green); ****p < 0.0001, n.s., non-significant. For the statistical analysis in (G), we used two-way ANOVA, and the p values are indicated as **p < 0.01 and ****p < 0.0001. Vem, vemurafenib; 5FU, 5-fluorouracil; Dox, doxorubicin; and Iri, irinotecan. See also Figure S5 . promoting efficient ATM activation and 53BP1-dependent end joining was further supported by experiments in conditional Trf2 knockout MEFs. Conditional inactivation of the Shelterin subunit TRF2 results in telomere deprotection, which normally leads to ''spaghetti chromosomes,'' formed as a consequence of the fusion of dysfunctional telomeres by 53BP1-dependent end joining (Chapman et al., 2013) . We found that treating Trf2-deficient MEFs with BRAF inhibitors (but not MEKi) or depletion of IKKa reduced telomere-telomere fusions. We attribute this effect to the reduction in the co-recruitment of 53BP1 and RIF1 at dysfunctional telomeres. These results highlight the importance of BRAF and IKKa signaling for efficient ATM signaling and subsequent repair following DNA damage. Finally, we present evidence that clinically approved BRAF inhibitors could be repurposed for use in combination with DNAdamaging chemotherapies to target relevant cancers. This conclusion is based on our findings that the BRAF inhibitors vemurafenib or AZ628, when combined with 5-FU+Iri, effectively eradicate two different metastatic tumors that had acquired therapeutic resistance in human patients, although we cannot directly ascribe these results to the effect of BRAF inhibition on IKKa. Until now, the clinical use of BRAF inhibitors has focused on BRAF mutant (primarily BRAFV600E) tumors. Our findings demonstrating that BRAF inhibition synergizes with DNAdamaging drugs independent of BRAF mutation status therefore expands the potential target population that would benefit from this therapeutic approach. In addition, we have shown that compounds that are primarily ineffective in CRC but are used in other types of cancer (e.g., doxorubicin) should be reconsidered in combination treatments with BRAF inhibitors. Our results will prompt further preclinical and clinical studies to understand the broader utility of BRAF inhibitors beyond their current applications.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Animal Studies
Fragments of human colorectal tumors obtained from MARbiobank with the informed consent of patients and following all recommendations of Hospital del Mar' Ethics Committee, the Spanish regulations, and the Helsinki declaration's Guide were transplanted and expanded in the cecum of nude mice as orthoxenografts. To perform in vivo drug testing, equivalent pieces of individual tumors were implanted orthotopically in the wall of the cecum of nude mice. When tumors were detectable by palpation (4-5 weeks), animals were randomly ascribed to the different groups of treatment. Vemurafenib (50mg/kg) was administered orally every day, and 5-FU and irinotecan (50mg/kg each) every 4 days intravenously. After 21 days of treatment, mice were euthanized and tumors collected, photographed, measured and processed for immunohistochemistry examination. In a parallel experiment, animals were equally treated and left for survival analysis. In all our procedures, animals were kept under pathogen-free conditions, and animal work was conducted according to the guidelines from the Animal Care Committee at the Generalitat de Catalunya. The Committee for Animal Experimentation at the Institute of Biomedical Research of Bellvitge (Barcelona) approved these studies.
Patient-derived tumoroids
For tumoroids generation, primary or xenografted tumors were disaggregated in 1mg/mL collagenase II (Sigma) and 20 mg/mL hyaluronidase (Sigma), filtered in 100 mm cell strainer, and seeded in Matrigel (BD Biosciences) as described (Sato et al., 2011) . Tumoroids were expanded by serial passaging and kept frozen in liquid Nitrogen for being used in subsequent experiments. Mutations identified in the different tumors were: IMIM#1, EGFR(S464L) and TP53(I254T); IMIM#3, NRAS(Q61K), TP53(R175H), and EGFR(E928K); IMIM#5, KRAS(G12D); IMIM#6, KRAS; and IMIM#9, KRAS, NRAS and BRAF WT.
Cell lines CRC cell lines LIM1215 (KRAS and BRAF wild-type), Caco2, DLD1, SW480 and HCT116 (KRAS mutated), WiDr and HT29 (BRAF mutated) were obtained from the ATCC. IKKa wild-type and knock out MEFs were kindly provided by Michael Karin (UCSD, La Jolla). SV40-LT-immortalized TRF2 FL/FL were previously described (Celli and de Lange, 2005) . All cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) plus 10% fetal bovine serum (Biological Industries) and were maintained in a 5% CO 2 incubator at 37 C.
METHOD DETAILS
Tumoroid viability assays 600 single tumoroid cells were plated in 96-well plates in Matrigel. After 4 days in culture, we treated growing tumoroids with 5-FU, Irinotecan, doxorubicin, AZ628, vemurafenib or combinations for 72 hours at the indicated concentrations. Cell viability was determined using the CellTiter-GloÒ 3D Cell Viability Assay (Promega) following manufacturer's instructions in an Orion II multiplate luminometer (Berthold detection systems). Data were calculated as mean ± standard deviation from 3 independent experiments conducted in triplicates. Cell lysis and Western Blot (WB) Cells were lysed 20 min at 4 C in 300 mL of PBS plus 0.5% Triton X-100, 1 mM EDTA, 100 mM NA-orthovanadate, 0.25 mM phenylmethylsulfonyl fluoride, and complete protease inhibitor cocktail (Roche). Lysates were analyzed by western blotting using standard SDS-polyacrylamide gel electrophoresis (SDS-PAGE) techniques. In brief, protein samples were boiled in Laemmli buffer, run in polyacrylamide gels, and transferred onto polyvinylidene difluoride membranes. The membranes were incubated overnight at 4 C with the appropriate primary antibodies. After being washed, the membranes were incubated with specific secondary horseradish peroxidase-linked antibodies from Dako and visualized using the enhanced chemiluminescence reagent from Amersham.
Cell fractionation
For cytoplasm/nuclear/chromatin separations, cells were lysed in 10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, and 0.05% NP-40 (pH 7.9) for 10 min on ice and centrifuged at 3,000 rpm. Supernatants were recovered as the cytoplasmic fraction, and the pellets were lysed in 5 mM HEPES, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol, and 26% glycerol and sonicated for 5 min three times to recover the soluble nuclear fractions. The remaining pellet included the chromatin fraction. Lysates were run in SDS-PAGE and transferred onto Immobilon-P transfer membranes (Millipore) for western blot analysis.
immunoprecipitation Assay For precipitation assay, control and UV-treated cells were crosslinked with dithiobis succinimidyl propionate (DSP, Pierce) 10 min at room temperature and then disrupted in RIPA buffer plus protease inhibitor cocktail (Roche). Cells were then centrifuged at 13,000 rpm for 15 min, and supernatants were incubated with 5 mg of anti-IKKa(p45) antibody. Precipitates were captured with 35 mL of protein A-Sepharose, extensively washed, and analyzed by WB. In most of the experiments, we used the Clean-Blot IP Detection Kit as secondary antibody.
Immunohistochemical Staining (IHC)
Tissues were fixed in 4% formaldehyde overnight at room temperature and embedded in paraffin. 4 mm paraffin embedded sections were first deparaffinized in xylene. IHC was performed following standard techniques with EDTA-or citrate-based antigen retrieval and developed with the Envision+ System HRP Labeled Polymer anti-Rabbit or anti-Mouse and 3,3 0 -diaminobenzidine (DAB) from DAKO. Images were obtained with an Olympus BX61 microscope.
Immunofluorescence (IF) analysis
For cell lines and tumoroid immune-fluorescence, cells were directly fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100 (Pierce), washed and incubated overnight with the corresponding primary antibodies. Secondary antibodies were the Alexa Fluor TM from Invitrogen. ProLong TM Diamond Antifade Mountant plus DAPI was used as mounting medium. Images were taken in an SP5 upright confocal microscope (Leica).
Peptide Nucleic Acid (PNA) Fluorescence In Situ Hybridization (FISH) and IF-FISH Cells were treated with 0.2 mg/ml of colcemid for 90 minutes to arrest cells in metaphase. Trypsinized cells were incubated in 75 mM KCL, fixed with methanol:acetic acid (3:1), and spread on glass slides. To preserve chromosome architecture the slides were rehydrated in PBS for 5 minutes, fixed in 4% formaldehyde for 5 minutes, treated with 1 mg/ml of pepsin for 10 minutes at 37 C, and fixed in 4% formaldehyde for 5 minutes. Next, slides were dehydrated in 70%, 85%, and 100% (v/v) ethanol for 15 minutes each and then air-dried. Metaphase chromosome spreads were hybridized with telomeric TAMRA-TelG 5 0 -(TTAGGG)3-3 0 PNA probe (Bio-synthesis) and slides were mounted using ProLong Gold antifade with DAPI (Life Technologies). Chromosome images and telomere signals were captured using Zeiss Axio Imager M1 microscope equipped with an ORCA-ER camera (Hamamatsu) controlled by Volocity 6.3 software (Improvision). For IF-FISH, cells grown on #1.5 glass coverslips were fixed for 5 minutes in cold methanol. Cells were washed twice for 5 min in PBS, incubated for 30 min in blocking solution (1 mg/ml BSA, 3% goat serum, 0.1% Triton X-100, 1 mM EDTA in PBS), and then incubated overnight with primary antibody against 53BP1 and secondary antibody anti-rabbit Alexa Fluor 488 secondary antibody for 1 hr and 30 min, in blocking solution with 5 min washes in PBS in-between. After dehydration of the cells, FISH experiments were performed as described above. Slides were mounted with ProLong Gold antifade containing DAPI and images were acquired with an Olympus FLV1000 inverted microscope equipped with a 63X oil objective.
Laser microirradiation induced DNA damage HT29 cells were seeded on 35 mm glass bottom dish (Ibidi, 81158) and pre-sensitized for 48h with 10 mM BrdU. Cells were transferred to Olympus FV1000 confocal LSM with heated stage. Laser microirradition was performed in a stripe shape with a 405 nm laser focused through 40x objective (400mW at objective, 50 scans). 1 hour after DNA damage induction, cells were fixed and processed for IF.
Knock down and knock out assays Lentiviral particles including shRNAs against IKK subunits were obtained from Sigma (table) . The TRC2 pLKO.5-puro non-mammalian shRNA plasmid (SHC202) was used as negative control. siRNAs employed were ON-TARGET plus siRNA SMARTpool purchased from GE Dharmacon. RNA interference (RNAi) transfections were performed using Dharmafect Trasfection Reagent (Dharmacon) in a forward transfection mode using manufacturer's guidelines.
Deletion of floxed alleles in Trf2 FL/FL cells was carried out with either Ad-GFP or Ad-GFP-Cre adenovirus (Vector Biolabs, ref. 1060 and 1700) and checked by WB.
Cell cycle analysis
Cell cycle was determined by flow cytometry using the standard Propidium Iodide staining-based protocol in the LSR-Fortessa analyzer (BD Biosciences).
Comet Assay
Comet assays were performed using CometAssayÒ Trevigen Kit (4250-050-K) following manufacturer's instructions. Pictures were taken using a Nikon Eclipse Ni-E epifluorescence microscope and tail moment was calculated using the OPENCOMET plugin for Fiji.
Kinase Assay
In vitro kinase assays were performed as previously described (Espinosa et al., 2003) . In brief, 5 mg of GST or GST-ATM (Aa1911-2063) were incubated with 200 ng of recombinant human IKKa (ab102103) or 10 mg of cell lysates from WT or IKKa KO cells at 30 C for 30 minutes in the presence of ATPgP
32
. Reactions were stopped by adding loading buffer, run in a polyacrylamide gel and developed in autoradiograph film.
Mass Spectrometry Analysis
Cell lysates obtained in the different experimental conditions were processed and digested with trypsin and endoproteinase LysC with a ratio enzyme:sample of 1:10 for both enzymes (w:w). Samples were then subjected to phospho-peptide enrichment using titanium dioxide (TiO 2 ) beads, and phospho-enriched samples were analyzed by LC-MS/MS. To identify IKKa-dependent phosphopeptides, samples were injected with a 120-minute chromatographic gradient in an Orbitrap Velos Pro with a data-dependent acquisition method using CID fragmentation for the top 20 most intense precursor ions and multistage activation. In the UV-activation experiment, samples were acquired with a 90-minute gradient in an Orbitrap Fusion Lumos with a data-dependent acquisition method using top speed, HCD fragmentation and ion-trap detection. In both cases, the resulting data were analyzed with the Proteome Discoverer software v1.4, using the search algorithm Mascot (v2.5) against a Human protein database (Uniprot, v2015) with oxidation (Met), and phosphorylation (Ser, Thr, Tyr) as variable modifications. Carbamidomethylation (Cys) was set as fixed modification and a mass tolerance of 7 ppm (MS1) and 0.5 Da (MS2) were used. Only peptides with a false discovery rate below 5% were considered for quantitative analysis. Peptides relative abundance was estimated with the area under the curve of extracted ion chromatograms. Protein network was generated using cytoscape software (https://cytoscape.org).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters, including number of events quantified, standard deviation, and statistical significance are reported in the figures and in the figure legends. Statistical analysis has been performed using GraphPad Prism6 software (GraphPad) and p < 0.05 is considered significant. Two-sided Student's t test was used to compare differences between two groups and TwoWay ANOVA test was used to compare differences among multiple groups. Each experiment has been repeated at least twice.
DATA AND CODE AVAILABILITY
MS data are available at PRIDE EBI-EMBL database with identifier PRIDE: PXD008932.
Row data from our manuscript is available at https://doi.org/10.17632/k6xkjc2bf7.1 A Figure S1 . 
